IPN60090 (dihydrochloride)

$580$5,000

Products Details

Product Description

– IPN-60090 dihydrochloride is an orally active and highly selective inhibitor of glutaminase 1 (GLS1; IC50=31 nM), with no activity observed against GLS-2. IPN-60090 dihydrochloride exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 dihydrochloride can be used for solid tumors research, such as lung and ovarian cancers[1][2].

Web ID

– HY-103671A

Storage Temperature

– 4°C (Powder, sealed storage, away from moisture and light)

Shipping

– Room Temperature

Applications

– COVID-19-immunoregulation

Molecular Formula

– C24H29Cl2F3N8O3

References

– [1]Maria Emilia Di Francesco, et al. Gls1 inhibitors for treating disease. WO2016004404A2.|[2]Michael J Soth, et al. Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. J Med Chem. 2020 Nov 12;63(21):12957-12977.

CAS Number

– 2102101-72-2

Molecular Weight

– 605.44

Compound Purity

– 99.05

SMILES

– O=C(NC)C1=CN(C[C@H](F)CCC2=NN=C(NC(CC3=NC(C)=CC(OC4CC(F)(F)C4)=C3)=O)C=C2)N=N1.[H]Cl.[H]Cl

Clinical Information

– Phase 1

Research Area

– Cancer; Inflammation/Immunology

Solubility

– DMSO : 170 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)

Target

– Glutaminase

Pathway

– Metabolic Enzyme/Protease

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=